Cargando…
Endothelial Injury and Glycocalyx Degradation in Critically Ill Coronavirus Disease 2019 Patients: Implications for Microvascular Platelet Aggregation
Coronavirus disease 2019 is caused by the novel severe acute respiratory syndrome coronavirus 2 virus. Patients admitted to the ICU suffer from microvascular thrombosis, which may contribute to mortality. Our aim was to profile plasma thrombotic factors and endothelial injury markers in critically i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449254/ https://www.ncbi.nlm.nih.gov/pubmed/32904031 http://dx.doi.org/10.1097/CCE.0000000000000194 |
_version_ | 1783574620660563968 |
---|---|
author | Fraser, Douglas D. Patterson, Eric K. Slessarev, Marat Gill, Sean E. Martin, Claudio Daley, Mark Miller, Michael R. Patel, Maitray A. dos Santos, Claudia C. Bosma, Karen J. O’Gorman, David B. Cepinskas, Gediminas |
author_facet | Fraser, Douglas D. Patterson, Eric K. Slessarev, Marat Gill, Sean E. Martin, Claudio Daley, Mark Miller, Michael R. Patel, Maitray A. dos Santos, Claudia C. Bosma, Karen J. O’Gorman, David B. Cepinskas, Gediminas |
author_sort | Fraser, Douglas D. |
collection | PubMed |
description | Coronavirus disease 2019 is caused by the novel severe acute respiratory syndrome coronavirus 2 virus. Patients admitted to the ICU suffer from microvascular thrombosis, which may contribute to mortality. Our aim was to profile plasma thrombotic factors and endothelial injury markers in critically ill coronavirus disease 2019 ICU patients to help understand their thrombotic mechanisms. DESIGN: Daily blood coagulation and thrombotic factor profiling with immunoassays and in vitro experiments on human pulmonary microvascular endothelial cells. SETTING: Tertiary care ICU and academic laboratory. SUBJECTS: All patients admitted to the ICU suspected of being infected with severe acute respiratory syndrome coronavirus 2, using standardized hospital screening methodologies, had daily blood samples collected until testing was confirmed coronavirus disease 2019 negative on either ICU day 3 or ICU day 7 if the patient was coronavirus disease 2019 positive. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: Age- and sex-matched healthy control subjects and ICU patients that were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well balanced with the exception that coronavirus disease 2019 positive patients were more likely than coronavirus disease 2019 negative patients to suffer bilateral pneumonia. Mortality rate for coronavirus disease 2019 positive ICU patients was 40%. Compared with healthy control subjects, coronavirus disease 2019 positive patients had higher plasma von Willebrand factor (p < 0.001) and glycocalyx-degradation products (chondroitin sulfate and syndecan-1; p < 0.01). When compared with coronavirus disease 2019 negative patients, coronavirus disease 2019 positive patients had persistently higher soluble P-selectin, hyaluronic acid, and syndecan-1 (p < 0.05), particularly on ICU day 3 and thereafter. Thrombosis profiling on ICU days 1–3 predicted coronavirus disease 2019 status with 85% accuracy and patient mortality with 86% accuracy. Surface hyaluronic acid removal from human pulmonary microvascular endothelial cells with hyaluronidase treatment resulted in depressed nitric oxide, an instigating mechanism for platelet adhesion to the microvascular endothelium. CONCLUSIONS: Thrombosis profiling identified endothelial activation and glycocalyx degradation in coronavirus disease 2019 positive patients. Our data suggest that medications to protect and/or restore the endothelial glycocalyx, as well as platelet inhibitors, should be considered for further study. |
format | Online Article Text |
id | pubmed-7449254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-74492542020-09-04 Endothelial Injury and Glycocalyx Degradation in Critically Ill Coronavirus Disease 2019 Patients: Implications for Microvascular Platelet Aggregation Fraser, Douglas D. Patterson, Eric K. Slessarev, Marat Gill, Sean E. Martin, Claudio Daley, Mark Miller, Michael R. Patel, Maitray A. dos Santos, Claudia C. Bosma, Karen J. O’Gorman, David B. Cepinskas, Gediminas Crit Care Explor Original Clinical Report Coronavirus disease 2019 is caused by the novel severe acute respiratory syndrome coronavirus 2 virus. Patients admitted to the ICU suffer from microvascular thrombosis, which may contribute to mortality. Our aim was to profile plasma thrombotic factors and endothelial injury markers in critically ill coronavirus disease 2019 ICU patients to help understand their thrombotic mechanisms. DESIGN: Daily blood coagulation and thrombotic factor profiling with immunoassays and in vitro experiments on human pulmonary microvascular endothelial cells. SETTING: Tertiary care ICU and academic laboratory. SUBJECTS: All patients admitted to the ICU suspected of being infected with severe acute respiratory syndrome coronavirus 2, using standardized hospital screening methodologies, had daily blood samples collected until testing was confirmed coronavirus disease 2019 negative on either ICU day 3 or ICU day 7 if the patient was coronavirus disease 2019 positive. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: Age- and sex-matched healthy control subjects and ICU patients that were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well balanced with the exception that coronavirus disease 2019 positive patients were more likely than coronavirus disease 2019 negative patients to suffer bilateral pneumonia. Mortality rate for coronavirus disease 2019 positive ICU patients was 40%. Compared with healthy control subjects, coronavirus disease 2019 positive patients had higher plasma von Willebrand factor (p < 0.001) and glycocalyx-degradation products (chondroitin sulfate and syndecan-1; p < 0.01). When compared with coronavirus disease 2019 negative patients, coronavirus disease 2019 positive patients had persistently higher soluble P-selectin, hyaluronic acid, and syndecan-1 (p < 0.05), particularly on ICU day 3 and thereafter. Thrombosis profiling on ICU days 1–3 predicted coronavirus disease 2019 status with 85% accuracy and patient mortality with 86% accuracy. Surface hyaluronic acid removal from human pulmonary microvascular endothelial cells with hyaluronidase treatment resulted in depressed nitric oxide, an instigating mechanism for platelet adhesion to the microvascular endothelium. CONCLUSIONS: Thrombosis profiling identified endothelial activation and glycocalyx degradation in coronavirus disease 2019 positive patients. Our data suggest that medications to protect and/or restore the endothelial glycocalyx, as well as platelet inhibitors, should be considered for further study. Lippincott Williams & Wilkins 2020-08-24 /pmc/articles/PMC7449254/ /pubmed/32904031 http://dx.doi.org/10.1097/CCE.0000000000000194 Text en Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Clinical Report Fraser, Douglas D. Patterson, Eric K. Slessarev, Marat Gill, Sean E. Martin, Claudio Daley, Mark Miller, Michael R. Patel, Maitray A. dos Santos, Claudia C. Bosma, Karen J. O’Gorman, David B. Cepinskas, Gediminas Endothelial Injury and Glycocalyx Degradation in Critically Ill Coronavirus Disease 2019 Patients: Implications for Microvascular Platelet Aggregation |
title | Endothelial Injury and Glycocalyx Degradation in Critically Ill Coronavirus Disease 2019 Patients: Implications for Microvascular Platelet Aggregation |
title_full | Endothelial Injury and Glycocalyx Degradation in Critically Ill Coronavirus Disease 2019 Patients: Implications for Microvascular Platelet Aggregation |
title_fullStr | Endothelial Injury and Glycocalyx Degradation in Critically Ill Coronavirus Disease 2019 Patients: Implications for Microvascular Platelet Aggregation |
title_full_unstemmed | Endothelial Injury and Glycocalyx Degradation in Critically Ill Coronavirus Disease 2019 Patients: Implications for Microvascular Platelet Aggregation |
title_short | Endothelial Injury and Glycocalyx Degradation in Critically Ill Coronavirus Disease 2019 Patients: Implications for Microvascular Platelet Aggregation |
title_sort | endothelial injury and glycocalyx degradation in critically ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation |
topic | Original Clinical Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449254/ https://www.ncbi.nlm.nih.gov/pubmed/32904031 http://dx.doi.org/10.1097/CCE.0000000000000194 |
work_keys_str_mv | AT fraserdouglasd endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT pattersonerick endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT slessarevmarat endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT gillseane endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT martinclaudio endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT daleymark endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT millermichaelr endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT patelmaitraya endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT dossantosclaudiac endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT bosmakarenj endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT ogormandavidb endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation AT cepinskasgediminas endothelialinjuryandglycocalyxdegradationincriticallyillcoronavirusdisease2019patientsimplicationsformicrovascularplateletaggregation |